Adaptimmune Therapeutics (ADAP) Projected to Post Quarterly Earnings on Wednesday

Adaptimmune Therapeutics (NASDAQ:ADAP) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

Adaptimmune Therapeutics Stock Up 3.7 %

NASDAQ:ADAP opened at $0.57 on Wednesday. The company has a market cap of $146.52 million, a PE ratio of -2.60 and a beta of 2.42. Adaptimmune Therapeutics has a twelve month low of $0.52 and a twelve month high of $2.05. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The company’s 50 day moving average is $0.59 and its two-hundred day moving average is $0.78.

Analyst Upgrades and Downgrades

Several research firms recently commented on ADAP. Guggenheim dropped their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. HC Wainwright decreased their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th. StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, Mizuho dropped their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $2.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.